Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders

NCT01571609 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-12-02

No results posted yet for this study

Summary

The purpose of the present study is to conduct a thorough and relevant physiology study of carriers and non-carriers of the gene variant X in order to determine the effect of the genetic variant on various metabolic parameters.

Conditions

Interventions

OTHER

first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer

FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes. HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes. Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes.

Sponsors & Collaborators

  • Lundbeck Foundation

    collaborator OTHER
  • Aarhus University Hospital

    collaborator OTHER
  • Vejle Hospital

    collaborator OTHER
  • Esbjerg Hospital - University Hospital of Southern Denmark

    collaborator OTHER
  • Steno Diabetes Center Copenhagen

    collaborator OTHER
  • University of Copenhagen

    collaborator OTHER
  • University of Aarhus

    lead OTHER

Principal Investigators

  • Niels Møller, Professor · University of Aarhus

  • Oluf B Pedersen, Professor · Steno Diabetes Center Copenhagen

  • Torben Hansen, Professor · Steno Diabetes Center Copenhagen

  • Jørgen Rungby, Professor · University of Aarhus

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-07-31
Completion
2014-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01571609 on ClinicalTrials.gov